Influenza A viruses (IAVs) are members of the family Orthomyxoviridae and genus Orthomyxovirus. Avian and mammalian species are the host of IAVs, which includes humans and dogs. Canine influenza virus (CIV) is an emerging pathogen that causes severe and acute respiratory diseases in dogs. This study monitored the antigen and antibody against CIV in dogs in the Republic of Korea (ROK) from 2016 to 2021. One thousand and seventy-two nasal swabs and 1,545 blood samples were collected from animal hospitals and animal shelters. Five nasal swabs in 2017 and seven in 2018 from stray dogs were positive for CIV according to RT-PCR. The prevalence of H3N2 CIV ranged from 9.5% to 24.8%, according to the hemagglutination inhibition (HI) assay. On the other hand, none of the serum samples from 2018 to 2021 showed seropositivity against the avian H5, H7, and H9 viruses. The HI titers for H3N2 ranged from 16 to 512. The distribution of HI titer 16–32 was 57.6% in seropositive samples. The pet dogs were vaccinated against CIV, but the stray and military dogs were unvaccinated. In 2017 and 2018, the seroprevalence of CIV in stray dogs was higher than in the other years, and viral RNA was detected in nasal swabs. It may mean previous exposure of stray dogs to CIV. With the increasing number of pet dogs and the close contact between humans and dogs, canines could serve as an intermediate host for transmitting IAVs to humans. Therefore, continuous surveillance of CIV is needed for public health and the potential emergence of novel zoonotic viruses.

Following the previous study, the toxicity of a single subcutaneous administration of the Thyrokitty injection (I-131) and the side effects that may occur at therapeutic doses were confirmed. The Thyrokitty injection (I-131) was administered subcutaneously once at a dose of 0, 2.0, 6.0, and 18.0 mCi/kg, 5 male and female rats per group, and mortality, general symptom observation, and weight measurement were performed for 2 weeks, followed by observation of autopsy findings. There were no deaths, and no statistically significant weight change was observed. Mild hair loss, fissures, and crusting were observed by general symptom observation, but it was not a toxic change related to the Thyrokitty injection (I-131). Gastric atrophy and a decrease in the size of the spleen were observed by the autopsy. As a results of single subcutaneous administration of the Thyrokitty Injection (I-131) to rats at a maximum dose of 18.0 mCi/kg, a decrease in the size of the spleen and gastric atrophy were observed as the dose of the Thyrokitty Injection (I-131) increased, which may be related to the test substance. No abnormal findings related to the Thyrokitty injection (I-131) were observed. Therefore, the approximate lethal dose of the Thyrokitty injection (I-131) was 18.0 mCi/kg or more. In addition, as reported for the treatment of feline hyperthyroidism with radioiodine (131I), side effects of the Thyrokitty injection (I-131) are expected to be extremely rare. Temporary dysphagia and fever may occur, but it will recover naturally. It should be administered with caution in cats with diseases such as urinary system, cardiovascular system, gastrointestinal system and endocrine system, especially with kidney disease. And it should not be used in cats who are pregnant, lactating, or likely. It is expected that the Thyrokitty injection (I-131) can be used for clinical treatment in Korea as a veterinary drug.

Radioiodine (131I) has been used for the treatment of feline hyperthyroidism since the 1990s in the USA and Europe, and it is recommended as the most effective treatment for feline hyperthyroidism because it has a high therapeutic effect, small side effects, and does not require anesthesia. In this study, the pharmacological properties of the Thyrokitty injection (I-131), which is being developed as a treatment for feline hyperthyroidism, using radioiodine (131I) as an active ingredient, was tested. The %cell uptake of the Thyrokitty injection (I-131) in FRTL- 5 thyroid cells was 0.410 ± 0.016%, which was about 18 times higher compared to Clone 9 hepatocytes, and it was decreased by 30.7% due to the competitive reaction with iodine (sodium iodide). In addition, the %cell growth of the FRTL-5 thyroid cells was reduced by 25.0% by treatment with the Thyrokitty injection (I-131). As a result of the tissue distribution test, the Thyrokitty injection (I-131) was distributed at the highest concentration at 0.083 hours (5 minutes) after subcutaneous administration to animals in most organs except the stomach, small intestine, large intestine, muscle and thyroid gland, and it was excreted mainly through the kidneys. The stomach and thyroid gland showed a typical distribution pattern observed when radioiodine (131I) was administered. In addition, about 78.45% of the total amount of excretion was excreted within 48 hours, of which more than 85% was excreted in urine. In conclusion, the Thyrokitty injection (I-131) has the same mechanism of action, potency, absorption, distribution, metabolism and excretion characteristics as radioiodine (131I) reported in connection with the treatment of feline hyperthyroidism. In the future, using the results of this study, it is expected that the Thyrokitty (I-131) could be safely used in the clinical treatment of feline hyperthyroidism.

Radioactive source terms are important factor in design, licensing and operation of SMR (Small Modular Reactor). In this study, regulatory requirements and evaluation methodology for normal operation on NuScale SMR, which received standard design certification approval on September 11, 2020 from US NRC, are reviewed. The radioactive waste management system of nuclear power reactor should be designed to limit radionuclide concentration in effluents and keep radioactive effluents at restricted area boundary ALARA according to 10 CFR 20 and 10 CFR 50 Appendix I. Also, in general, the coolant source term to calculate the off-site radiological consequences for normal operation of SMR should be determined by using models and parameters that are consistent with regulatory guide 1.112, NUREG- 0017 and the guidance provided in ANSI/ANS-18.1-1999, and the result should be corrected by reflecting the design characteristics of SMR. The coolant source term of NuScale, unlike the case of large NPPs, cannot rely solely on empirical source term data, because the NuScale source term is based on first principle physics, operational experience from recent industry, and lessons learned from large PWR operation. Fission products in reactor coolant are conservatively calculated using first principle physics in SCALE Code assuming 60 GWD/MTU. The release of fission products from fuel to primary coolant based on industry operational experience is determined as fuel failure fraction of 0.0066% for normal operation source term and 0.066% for design basis source term while coolant source term of large NPP is calculated by using ANSI/ANS-18.1 for normal operation and fuel failure fraction of 1% for design basis source term. Water activation products in reactor coolant are calculated from first principles physics and corrosion activation products are calculated by utilizing current large PWR operating data (ANSI/ANS 18.1- 1999) and adjusted to NuScale plant parameters. Also, because ANSI/ANS 18.1-1999 is not based on first principle physics models for CRUD generation, buildup, transport, plate-out, or solubility, NuScale has incorporated lessons learned by using ERPI’s primary water chemistry and steam generator guidelines to ensure source term is conservative and design of materials used cobalt reduction philosophy to help ensure the coolant source term are conservative. Based on the coolant source term calculated according to the above-described method, the annual releases of radioactive materials in gaseous and liquid effluents from NuScale reactor are evaluated. Currently, Small Modular Reactors such as ARA, SMART 100 are under review for licensing in Korea. This study will be helpful to understand how the reactor coolant system source terms are defined and evaluated for SMR.

As cable TV, which has been leading the paid broadcasting market, has given the lead to IPTV, which has huge communication capital, its competitiveness is gradually weakening. This study examines the operation status of local cable TV and seeks ways to strengthen competitiveness for survival. To this end, we conducted data analysis such as related statistics, broadcasting industry survey reports, IPTV growth reports, CMB management indicators, paid broadcasting literature data, marketing reports, industry success stories, and marketing mix and SWOT analysis. As a result, four strategies for strengthening the survival competitiveness of local cable TV, namely joint purchase apartment marketing strategy, influencer marketing strategy, relationship marketing strategy, and digital marketing strategy were derived. Therefore, the results of this study can contribute to the improvement of the competitiveness of local cable TV, which has been with local residents through close content, and can be used as basic data for establishing marketing strategies for local cable TV in the future.